Q4 2025 Earnings Presentation February 5, 2026 © 2026 Illumina, Inc. All rights reserved. Cautionary Notes Year-over-year (YoY) denotes a comparison against the same quarter of the previous fiscal year, while quarter-over-quarter (QoQ) or "sequential" denotes a comparison against the previous fiscal quarter. In addition, all references to China refer to our Greater China Region, which also includes Taiwan and Hong Kong. © 2026 Illumina, Inc. All rights reserved. 2 RGB: 229, 96, 0 RGB: 228, 189, 255 RGB: 255 ...

Consolidated Balance Sheets(In millions)December 28,2025December 29,2024ASSETS(unaudited)Current assets:Cash and cash equivalents$ 1,418$ 1,127Short-term investments21593Accounts receivable, net854735Inventory, net564547Prepaid expenses and other current assets238244Total current assets3,2892,746Property and equipment, net759815Operating lease right-of-use assets370419Goodwill1,1131,113Intangible assets, net210295Deferred tax assets, net454567Other assets449348Total assets$ 6,644$ 6,303LIABILITIES AND STOCK ...

The upcoming report from Illumina (ILMN) is expected to reveal quarterly earnings of $1.26 per share, indicating an increase of 46.5% compared to the year-ago period. Analysts forecast revenues of $1.16 billion, representing an increase of 4.6% year over year.The consensus EPS estimate for the quarter has been revised 2.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a ...

Core Insights - Illumina has entered a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA) to sequence up to 4,000 samples from 1,300 species in the Frozen Zoo, which is the world's most comprehensive biobank of living cells from endangered species [1][2][4] Company Overview - Illumina is a global leader in DNA sequencing and array-based technologies, focusing on innovation to improve human health through genomic insights [9] - The company collaborates with various organizations, including the SDZWA, to advance conservation efforts and promote ecological resilience [6][10] Industry Context - The collaboration aims to leverage multiomic technologies to enhance conservation science and address biodiversity loss, showcasing the importance of genomic data in protecting endangered species [3][4] - The Frozen Zoo, founded in 1975, holds over 11,500 samples from 4,000 unique individuals across 1,300 species, serving as a critical resource for conservation research [11]

Core Insights - Illumina, Inc. (ILMN) is scheduled to announce its fourth-quarter 2025 results on February 5, with adjusted earnings per share (EPS) of $1.34 in the last reported quarter, exceeding the Zacks Consensus Estimate by 15.5% [1] Q4 Estimates - The Zacks Consensus Estimate for fourth-quarter revenues is $1.16 billion, indicating a 4.6% growth from the previous year [2] - The earnings estimate is $1.26 per share, reflecting a 46.5% increase from the year-ago figures [2] Estimate Revision Trend - Earnings estimates for the fourth quarter have risen by 2.4% to $1.26 over the past 30 days [3] Factors Influencing Q4 Performance - The Core Illumina segment's performance may be impacted by macroeconomic challenges, including the Russia-Ukraine conflict and reduced U.S. government funding for the NIH [4] - The company faces cost exposure related to imports from its Singapore manufacturing facility, while the Chinese Ministry of Commerce has lifted its export ban on Illumina's sequencing instruments, although the company remains on the Unreliable Entities List [4] Positive Developments - Illumina is expected to benefit from the momentum of the NovaSeq X in Q4, with high-throughput volumes likely increasing due to strong clinical market demand outside of China [5] - The company exceeded its goal of high-throughput gigabases shipped and revenues on the X platform, indicating strong demand for sequencing [6] Revenue Projections - Sequencing Consumables revenues are projected to grow by 3.2% year-over-year in Q4, despite ongoing funding uncertainty affecting research customers [7] - Sequencing Instruments revenues may decline by 12.2% year-over-year, impacted by export restrictions in Greater China [8] Strategic Initiatives - Illumina's strategic focus includes growing its core sequencing business, scaling into multiomics, and enhancing services and software capabilities [11] - The launch of the Illumina Protein Prep assay and the introduction of BioInsight are expected to positively influence Q4 revenues [12] Earnings Prediction - Illumina has an Earnings ESP of +2.25%, indicating a higher likelihood of beating estimates [13]

此次整合标志着多组学研究新时代的开启，生物医学研究有望迎来新的发展机遇。 摘要 ： 基因测序巨头斥资3.5亿美元将蛋白质组学技术领导者纳入麾下，旨在为客户提供更全面的多 组学解决方案。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 美国加利福尼亚州圣迭戈——2026年1月30日，因美纳公司宣布已完成对蛋白质组学技术领 域领先企业SomaLogic的收购。此次交易总价值达3.5亿美元，另加高达7500万美元的绩效 里程碑款项。 这 一 收 购 标 志 着 因 美 纳 在 实 施 2024 年 提 出 的 多 组 学 战 略 过 程 中 取 得 重 要 进 展 。 通 过 整 合 SomaLogic高度差异化的蛋白质组学技术，因美纳将增强在基因组学与蛋白质组学领域提供 可扩展洞察的能力。 因美纳首席执行官Jacob Thay sen表示："欢迎SomaLogic团队加入因美纳，这是我们落实 2024年制定的多组学战略 的重要里程碑。" 此前，在2025年6月宣布收购协议时，因美纳曾表示预计该业务将在2027年实现非GAAP的 经营收入盈利。 ...

Core Viewpoint - Standard BioTools Inc. has completed the sale of SomaLogic to Illumina for $350 million upfront, with potential total proceeds of up to $425 million, marking a significant step in the company's strategic transformation and positioning for future growth [1][2]. Financial Details - The company received $350 million in upfront cash and is eligible for up to $75 million in near-term earnout payments based on performance metrics for 2025 and 2026 [2][12]. - Following the transaction, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million, which will support its inorganic growth strategy [4]. Strategic Implications - The sale is viewed as a major milestone in the company's strategic transformation, allowing it to pursue disciplined mergers and acquisitions to accelerate growth [2]. - Standard BioTools will receive a 2% royalty on net revenues from SOMAmer-based NGS library preparation kits for a duration of 10 years, along with a co-exclusive license for related intellectual property [3]. Operational Outlook - The company is on track to achieve positive adjusted EBITDA by 2026, indicating a focus on improving operational performance post-transaction [1].

Core Insights - Illumina has completed the acquisition of SomaLogic, enhancing its capabilities in proteomics and multiomics, which will facilitate faster drug discovery and improve healthcare outcomes [1][2][5] Group 1: Acquisition Details - The acquisition was finalized for $350 million in cash, with potential additional payments of up to $75 million based on performance milestones [6] - This acquisition builds on a prior partnership that began in late 2021, aimed at integrating SomaLogic's technology with Illumina's high-throughput NGS platforms [5] Group 2: Strategic Implications - The combination of SomaLogic's proteomics technology with Illumina's existing innovations is expected to provide scalable insights across genomics and proteomics, enhancing customer outcomes [2][3] - Illumina aims to leverage this acquisition to strengthen its position in the growing proteomics market, thereby complementing its high-throughput sequencing business [3] Group 3: Product Integration and Support - Illumina will ensure continuity of products and services as SomaLogic's portfolio is integrated into its offerings, maintaining support for existing customers [4][5] - The integration will allow customers to generate rich multiomic datasets, utilizing a combination of SomaLogic's and Illumina's technologies [2][5]

Core Viewpoint - Canaccord Genuity has raised the target price for Illumina from $130 to $150 while maintaining a "hold" rating [1] Group 1 - The target price adjustment reflects a positive outlook on Illumina's performance [1] - The "hold" rating indicates a cautious approach towards investing in Illumina at the current price level [1]

Core Insights - Chicago Partners Investment Group LLC increased its holdings in Illumina, Inc. by 90.5% in Q3, owning 9,908 shares valued at $969,000 after acquiring an additional 4,708 shares [2] - Other institutional investors also increased their stakes, with Empowered Funds LLC raising its position by 113.7% and acquiring 9,284 shares worth $737,000 [3] - Illumina reported Q3 earnings of $1.34 per share, exceeding estimates of $1.16, with revenue of $1.08 billion, slightly above the consensus of $1.07 billion [5] Institutional Holdings - 89.42% of Illumina's stock is owned by institutional investors and hedge funds [3] - Notable increases in holdings include GAMMA Investing LLC, which boosted its stake by 199.5% in Q2, now owning 2,465 shares valued at $235,000 [3] Stock Performance - Illumina's stock opened at $150.28, with a market cap of $22.96 billion, a PE ratio of 33.70, and a 52-week range of $68.70 to $155.53 [4] - The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12, and a current ratio of 1.43 [4] Analyst Ratings - Barclays raised its price target for Illumina from $100.00 to $110.00, maintaining an "underweight" rating [6] - Six analysts rated the stock as a Buy, twelve as Hold, and two as Sell, with an average target price of $124.47 [6] Insider Transactions - Director Scott Gottlieb acquired 500 shares at an average cost of $122.13, increasing his ownership by 4.16% [7] - Insider Scott M. Davies sold 323 shares at an average price of $136.09, resulting in a 1.77% decrease in his ownership [8] Company Overview - Illumina, Inc. is a global life sciences company specializing in genetic analysis systems, headquartered in San Diego, California [9] - The company offers next-generation sequencing platforms, microarrays, and related technologies for various research applications [10]